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It has long been recognised that some very rare
forms of cancer predisposition, such as
retinoblastoma, are caused by inherited gene
mutations [7].  It is only within the last decade or
so, however, that rapid progress has been made in
understanding the role that inherited mutations
also play in determining a proportion of the more
common cancers, including breast, colorectal and
ovarian cancer [1,2,3,4,6,8,9,10].  Although there
is still uncertainty about the precise contribution
of inherited predisposition genes to the incidence
of these cancers, the available evidence suggests
that breast, colorectal and ovarian cancer have a
number of common genetic features:
• A small proportion of these cancers (about
5%) are caused by inherited gene mutations
which, though comparatively rare, confer very
high lifetime risks of developing cancer.  In
some cases these lifetime risks may be as high
as 80%.
• Cancers caused by these high-penetrance
genes are likely to occur at an earlier age than
sporadic cancers, and 15–20% of the cancers
diagnosed in people under the age of 50 may
be accounted for by these genetic mutations.
• Carriers of known genetic mutations which
confer high lifetime risks of developing
breast, colorectal or ovarian cancer are also at
a somewhat increased risk of developing
certain other forms of cancer.
• A further 10–20% of breast, colorectal and
ovarian cancers may be caused by other
inherited predisposition genes which are less
penetrant but which confer some increased
risk (more than 3 times the general population
risk).  These “medium risk” genes are only
beginning to be identified.
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• Familial clustering of the more common
cancers may also be influenced by
environmental and lifestyle factors as well as
by chance.
CANCER SERVICES IN EUROPE
Individual countries in Europe offer a wide
range of types of health services to their
population.  This variation reflects differences in
the balance between nationally and privately-
funded services, in the wealth and size of the
countries, in the acceptance and establishment of
genetic services, and in the demands made upon
the services by the population and their perceived
needs.  While many services have developed as a
result of evidence from the medical literature,
others have been developed as a result of patient
pressure and medical practitioner interest, often
modified to allow a country to offer that which is
affordable.
Hence, when it comes to cancer services across
a range of countries in Europe, it is not surprising
to find that there is wide variation in the basic
services available and the equity with which they
are offered.  From a survey of 89 centres in 34
countries it is possible to document the range of
services currently available in Europe (Table 1;
Figures 1–3).  For population breast screening,
the majority of countries offer breast screening
by mammography from 50 years of age.  In most
of these countries this occurs every two years.  A
few countries start screening from an earlier age
(between 30 and 50 years of age), and offer
mammography every one to five years.  As a
consequence of this wide variation, it is not
surprising to find that services for individuals
perceived to be at increased risk on the basis of
their family history also cover a wide spectrum
and involve a range of different professional
disciplines.
SERVICES FOR CANCER GENETICS
Cancer Genetics is a new field, and the
organisation of services in this area may be
Fig. 1.  Breast Screening by Mammography: High Risk Women: EC Countries.  Open circles represent screening
from age x, or n years younger than youngest affected relative.  Closed circles represent screening from n years
younger than youngest affected relative, age not specified.  Solid bars represent each screening event.
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Fig. 2.  Breast Screening by Mammography: High Risk Women: Non-EC Countries.  Open circles represent
screening from age x, or n years younger than youngest affected relative.  Closed circles represent screening from n
years younger than youngest affected relative, age not specified.  Solid bars represent each screening event.
Fig. 3a.  Referral Breakdown.  FCR = Familial Cancer Referrals;           = Breast Only;           = Breast/Ovarian;
           = Including Male Breast;          = FAP / HNPCC;           = Other.
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initiated by Clinical Genetic Services or through
Oncology, Surgery and other departments, where
individuals with a special interest arrange to see
individuals with a family history of cancer.
Many are currently being provided as part of
research projects.  Government Health
Departments are reluctant to provide funding for
such services until evidence-based audit can ensure
their cost-effectiveness; this is not yet available.
The acceptance and recognition of genetics as a
speciality is important for service development.
The growth of cancer genetics services will
depend upon the infrastructure and network of
Genetics Centres and other clinical services in the
country including primary care.  Good
communication between different Centres
promotes the development of compatible and
coordinated services which can be evaluated over
time.  The level of public awareness of genetic
issues is reflected in demand for this service.
Other factors influencing the level of services
include the tradition of screening (e.g.
thalassaemia in Mediterranean countries), the
degree of development of registers for genetic
conditions and cancer, and the acceptance of the
role of genetic counsellors.
In the majority of countries in Western Europe,
services for familial breast cancer are provided
with funding from the Government, but even in
that situation, this type of service is only available
to a percentage of the population.  A smaller
number of countries have services funded by both
the Government and from Research funds, and in
those countries where the only funding for service
is from research or Health Insurance and private
practice, the number of individuals for whom this
is available will be a small percentage of those at
risk.
POSITION IN THE UK
In the UK, Regional Genetics Centres have
been established for many years, and most
specialised genetic counselling for cancer
susceptibility is organised from the Genetic
Fig. 3b.  Referral Breakdown.  FCR = Familial Cancer Referrals;           = Breast Only;           = Breast/Ovarian;
           = Including Male Breast;           = FAP / HNPCC;           = Other.
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Centres.  However, there is increasing awareness
that education and referral guidelines for primary
care physicians is important.  This would allow a
collaborative relationship to be developed with
primary health care services, helping them to act
as gatekeepers for the prioritisation of referrals
for genetics services.  A second “layer” of service
provision is envisaged in cancer units where
individuals at moderately increased risk can be
managed.  This would ensure that only high-risk
individuals, in whose families it is probable that a
genetic cancer predisposition is segregating, are
seen in genetics centres.
The most appropriate structure for such a
service is likely to be:
1. A “gatekeeper” function of primary care, with
guidelines and educational material provided by
the genetics service, to ascertain individuals
with a positive family history of cancer and
refer individuals on to either 2. or 3.
2. A network of “moderate-risk” clinics, possibly
multidisciplinary, and perhaps based in Cancer
Units and other clinics (oncology; breast
surgical).  These would be manned by trained
genetic counsellors (who may be doctors,
nurses or genetic associates), with oncologists
and other relevant clinicians (surgeons;
gastroenterologists).  Counselling and risk
assessment would be provided, appropriate
clinical surveillance protocols instituted and
audited, and referrals arranged for high-risk
individuals to the local genetics centre.
3. The genetics service, which should concentrate
on high-risk families, staffed by clinical
geneticists and genetic counsellors.  These
would provide genetic counselling and
predictive testing, backed up by appropriate
molecular expertise and psychological support
as necessary.  There should be facilities for the
long-term audit of surveillance protocols.  This
would be most appropriately monitored
centrally, within the genetics centre.
It is apparent that because of its large scale, such
a service must rely heavily on genetic counsellors
and clinicians with an interest in a specialised area
of genetics rather than geneticists alone.  There
should be a high degree of coordination and
collaboration between disciplines, particularly as
many countries will initiate cancer genetics
services from oncology or other (non-genetic)
clinical services.
In the UK, genetic counselling is currently
offered by consultant clinical geneticists supported
by specialist registrars and genetic counsellors.
The genetic counsellors are usually nurses who
have received training (often “in house”) in
genetics.  However, there are increasing numbers
of graduates without a nursing background who
have attended a course in genetic counselling.
These genetic associates would also potentially
have an important role to play in delivering the
cancer genetics service.  The career structure of
these individuals is still being developed.  Genetic
counsellors are likely to play an important role in
overseeing the “gatekeeper” functions of primary
care.
MSc. courses in genetic counselling are being
developed.  In the UK, one two-year course is
available at Manchester University (since 1992),
and modules in Cancer Genetics are now available
in some other UK centres as part of genetics or
nursing curricula.  A working party was convened
in 1994 by the Genetic Nurses and Social Workers
Association in response to the debate about the role
of nurses in the activities of a Regional Genetic
Centre.  The Association of Genetic Nurses and
Counsellors (AGNC) has developed guidelines for
training, assessment of competency, and the most
appropriate role and responsibilities of genetic
counsellors [11,12].  They are also addressing the
career progression for such counsellors.  This has
coincided with the decision to produce educational
guidelines and the normalisation of requirements
for specialist nurse practice in all areas of health
care (UK Central Council, the statutory regulatory
body for nursing practice in the UK).
POSITION THROUGHOUT THE REST
OF EUROPE
Throughout the remainder of Europe, the
recognition and provision of genetics services
varies widely, influenced by historical,
geographic, political and economic factors.  A
BIOMED 1 survey examined services in
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European countries [5].  Multidisciplinary
Regional Genetics Centres are only well
established in the UK, Netherlands and Belgium,
and genetics is only recognised as an official
speciality in 20 of 31 European countries [5].
The highest reported proportions of genetically-
trained clinicians are in Belgium, Bulgaria,
Cyprus, the Czech Republic, Hungary, Finland,
the Netherlands, Germany, Greece, Israel and the
Ukraine; the UK has relatively few, despite being
one of the first countries in which genetics was
recognised as a speciality.
The presence of cancer registries and genetics
registers, particularly those recording data on
cancer-predisposing syndromes, provides a
positive impetus for the development and
coordination of cancer services.  Such registers
are well developed in the UK, Belgium, Finland,
the Netherlands, Norway, Poland, Sweden and
Denmark.  Others are being developed in Cyprus,
Hungary, Latvia, Romania, Slovenia, Switzerland
and the Ukraine.  Several European countries
have developed national networks for
standardisation of cancer genetics services.
These include the Cancer Family Study Group in
the UK, the Danish Breast Cancer Collaborative
Group, and the Netherlands National Registry of
Hereditary Breast Cancer Families.  In France,
“Centres Against Cancer” (CLCC) are supported
by a French charity, the League Against Cancer,
which is part of the network known as the
Genetics and Cancer Group from the FNCLCC
(Federation Nationale des Centres de Lutte
Contre le Cancer).  This group fosters nation-
wide collaboration in the conduct of the
management of genetic cancer susceptibility,
including oncologists, radiotherapists, surgeons
and geneticists involved in the field, and has
initiated the concept of “oncogeneticists”.  Other
specialist organisations which encourage
international collaboration in research and
management of hereditary cancers include
EUROFAP and ICG-HNPCC (Colorectal cancer
susceptibility).
There follow some details about cancer
genetics services in selected countries in Europe;
further information is tabulated and shown
graphically (Table 1, Figures 1–3).
In Denmark, clinical genetics was only
recognised as a medical speciality very recently
(1996), so that the responsibilities and training of
doctors who offer genetic counselling have not
yet been clearly delineated.  Specialist courses in
cancer genetics are available for doctors but not
yet for associates, and patient support groups are
not yet well developed.  However, Denmark runs
a cancer genetics registry for individuals with
Familial Adenomatous Polyposis (FAP) and
colorectal cancer, and cancer genetics services
are becoming well-developed, with the
acceptance of a role for nurses in selecting high-
risk individuals from peripheral units.
In the Netherlands there is a well-developed
network of Regional Clinical Genetics centres
and family cancer clinics in Dutch medical
academic centres.  These offer genetic
counselling and DNA diagnosis.  There is an
independent National Registry for families with
hereditary cancer (established in 1993) which is
managed by the Foundation for the Detection of
Hereditary Tumours (supported by the Ministry
of Health).  The aims of the National Registry
are: 1. to promote surveillance in families with
hereditary cancer; 2. to guarantee the continuity
of surveillance; and 3. to promote research.
Referrals to the clinical genetics centres for
genetic counselling are arranged as appropriate.
These activities are perceived as complementary.
In France, a network of cancer genetics clinics
has developed, initiated in 1986 by a group with
research interests in hereditary breast and ovarian
cancer (HBOC) situated in Lyon.  The Lyon
clinical service was initially focused on obtaining
a clinical resource for research.  However, the
need to provide a clinical service for the families
ascertained led on to the development of a
network of clinics in the Centres Against Cancer
(CLCC) referred to above.  Nurses and genetic
counsellors do not yet have a significant role in
service delivery.
In Belgium all genetic counselling is offered
by doctors, some of whom are oncologists with
training in genetics.  There are some research-
based genetic counsellors (nurses, social workers,
psychologists) but there is no formalised training
or role for these.
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In Germany, counselling is exclusively offered
by doctors.  There is a multicentre inter-
disciplinary network for the management of
hereditary breast cancer, established in 1995
under the auspices of the Ministry of Health
Cancer Programme, and several task forces were
set up to promote collaboration.  This advised the
Deutsche Krebshilfe on its National BRCA1
research funding scheme, and in January 1997
ten centres, located in medical schools
throughout Germany, were funded by a DM 10
million research grant to develop a
comprehensive service structure to include the
counselling and molecular aspects of this work,
within three years.  There are currently few
formal genetics centres, but several centres offer
molecular testing and counselling for specific
genetic conditions such as FAP or MEN.  Self-
help groups exist and there is a newsletter for
FAP families.
In Italy there are several relatively autonomous
regions which are currently looking for funding
to set up a network of genetics centres; this
application is being co-ordinated in Milan
(National Cancer Institute) with a five-year
research grant; no genetics nurses are employed
within the existing (research-based) services.
Clearly to a certain extent the ability to offer a
population-based service is related to the wealth
of the country as well as to the established nature
of medical genetics in medical practice (Table 1).
Each country and sometimes different centres in
the same country will offer different screening
protocols for women at an increased risk of
breast and other cancers.  For breast cancer it can
be seen in Figures 1 and 2 that the mammo-
graphic screening offered to women at twice the
population risk varies widely and until further
evidence is available to inform such procedures
this will continue to be the case.
The types of family histories selected for
referral to different centres can also be seen to
vary.  This depends upon the interests of
individuals running the Clinic.  Where referrals
for all types of history are accepted, a history of
breast cancer is currently the most common
reason for referral (Figure 3).
Audit of cancer genetics services is important,
as the services develop, and audit is well-
developed in Belgium, Denmark, Finland,
France, Germany, Israel, Italy, the Netherlands,
Norway, Sweden, Poland and the UK (Table 1).
ROLE OF GENETIC COUNSELLORS
Currently the employment of genetic
counsellors within the cancer genetic services
varies a great deal between countries.  The UK
has several genetic counsellors attached to each
Regional Genetics centre.  Their roles include
interviewing probands, constructing pedigrees,
confirming diagnoses and stratifying risk
estimates.  Many will act as the primary genetic
counsellor for cancer genetics.  They maintain
screening protocols, organise clinics, liase with
other health professionals, and may undertake
home visits.  They may obtain samples for
research studies, and co-ordinate such research.
They are also becoming involved in the provision
of educational material for patients and health
professionals, and may help in the development
of patient support groups.  In some Centres in the
UK, they have considerable autonomy in
delivering genetic counselling for specific cancer
genetic referrals within a structured framework
supervised by the clinical genetics departments.
The Cancer Family Study Group and the ICRF
cancer genetic nurse support group help maintain
uniformity of standards.
The participation of genetic counsellors in the
provision of such services in other European
countries is much less established, and in most
cases any co-workers that are employed are
involved in research or organisational activities.
There are over 800 genetics associates in 25
European countries, with highest rates in the UK,
Finland, Denmark, Israel and the Netherlands.
Greece is developing an MSc. course for genetic
counsellors.  Most countries, however, do not
make use of genetic counsellors in service
delivery to a significant degree, and there are
none in France, Germany, Latvia, Russia,
Slovenia, Spain or Turkey, and few in Croatia,
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Sweden, Italy or Norway.  In these countries
there is currently no formal training in genetics
for nurses.
Integral to the development of a broad-based
cancer genetics service is the provision of
education at several levels — for the public,
primary care health professionals, and hospital
clinicians.
Education of the public in issues of cancer
genetics is expanding, as part of the general
education for genetic issues, with the provision of
media coverage, museum exhibitions (such as the
specialist “Gene Dome” in Newcastle, UK, and
the Millennium exhibition at the Science
Museum in London) (Table 2).  There are also
proliferating world-wide web sites, for example
the Human Genome Information site, which can
be accessed at http://www.ornl.gov/
TechResources/Human_Genome/home.html (see
also Table 3).
The Cancer Family Study Group in the UK is
an example of a forum for health care
professionals, facilitating discussion of new
developments in cancer genetics, and
management issues.  Patient support groups are
beginning to be developed for cancer genetics,
either by cancer charities or genetics groups such
as the Genetic Interest Group (GIG) and Cancer
Link.  A new body, the Public Health Genetics
Unit (PHGU) was set up in 1997 to provide
education in genetics and a link between
academic research, clinical practice and the
development of NHS policy, and to promote
dialogue within the NHS between geneticists,
physicians, public health and primary care
professionals in relation to genetic issues.
Cancer genetics courses are beginning to be
offered by specialised centres such as Sestri
Levante (Italy), and the Cancer Genetics module
at the Royal Marsden Hospital (London).  In the
UK, modules for cancer genetics are being
introduced for nurses (ENB), and cancer genetics
is taught as part of the MSc. courses in genetics
and genetic counselling in Manchester, Cardiff
and London.  In Israel, there is a course for
genetic counsellors at the Hebrew University in
Table 2
Educational material on cancer genetics (examples from the UK in particular)
• Leaflets and other literature — widely produced, especially by Genetic Centres
• Videos - mainly from Genetic Centres
• Computerised packages — mainly from Genetics Centres and ICRF
• Pharmaceutical company literature (little as yet)
• Support Group Literature and Counselling
- for Ethnic minority groups e.g. Ashkenazi
- Cancer link, Cancer BACUP
- Cancer charities
• Exhibitions and Museums
- the Wellcome Trust
- Science Museum, UK:
1997 exhibition on “Genetic Choices”;
Millennium exhibition on “Genetics”
- “Genes are Us” travelling exhibition for UK shopping centres
- 1998 exhibition on “Mensch und Gene”, Exhibition Hall, Bonn
• The “Gene Dome” (Newcastle)
• The “Gene Shop” (Manchester Airport)
• Theatre in Education (Wellcome Centre for Medical Sciences)
• Television/Radio programmes
• Websites — see separate list
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Jerusalem, associated with the medical school at
Hadassah, Ein Karem.  Entry criteria include a
first degree in Biology with a high average mark.
The course lasts 3 years (30 credits per year), and
after graduation the student is required to work
under supervision in a genetic clinic for
recognition by the Ministry of Health.
Computer packages to help primary care
physicians assess risks from pedigree data are
being developed and evaluated in countries such
as the UK.  Their implementation would require
general agreement that this was beneficial, and
probably a genetic counsellor trained in cancer
genetics, based in primary care, would be
required to facilitate this.  Several models of
using such methods for prioritising referrals are
currently being assessed in the UK.
As evidence is obtained to demonstrate the
value of a Cancer Genetics service in reducing
morbidity and mortality from cancer, it is hoped
that this service will be developed with the
backing of the Health Ministries in all European
countries, and our Demonstration Project hopes
to aid this process.
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